Lichen Planus Developed During the Treatment with Nivolumab in a Patient with Lung Cancer: A Case Report and Literature Review
- Author:
Eunjung PARK
1
;
Taehan KOO
;
Mingyul JO
;
Jisook YOO
;
Jiho PARK
Author Information
1. Department of Dermatology, Veterans Health Service Medical Center, Seoul, Korea. serratus40@gmail.com
- Publication Type:Case Report
- Keywords:
Anti-programmed cell death receptor-1 antibody;
Anti-PD-1 antibody;
Lichen planus;
Nivolumab
- MeSH:
Aged;
Biopsy;
Carcinoma, Neuroendocrine;
Carcinoma, Renal Cell;
Cell Death;
Exanthema;
Hand;
Humans;
Immunoglobulin G;
Lichen Planus;
Lichens;
Lung Neoplasms;
Lung;
Melanoma;
T-Lymphocytes
- From:Korean Journal of Dermatology
2019;57(9):551-555
- CountryRepublic of Korea
- Language:English
-
Abstract:
Nivolumab is a fully-humanized IgG4 monoclonal antibody that competitively binds to the programmed cell death receptor-1 protein (an immune check-point molecule) present on activated T cells. Nivolumab is approved for the treatment of advanced melanoma, lung cancer, and renal cell carcinoma. It attenuates the inactivation of cytotoxic CD8+ T cells and, produces an antitumor effect; however it may be associated with immune-related adverse events, including the development of lichen planus (LP). A 72-year-old man presented with a 2-month history of multiple, polygonal, purplish papules on the dorsal aspect of both hands. He was diagnosed with large cell neuroendocrine carcinoma (LCNEC) of the lung 4 years earlier and was treated with nivolumab (3 mg/kg every 2 weeks) for 9 months. By the 14th course of nivolumab therapy, the patient developed multiple rashes on the dorsal aspect of both hands, and biopsy was consistent with findings of LP. We report a rare case of LP in a patient with lung cancer treated with nivolumab.
